Metabolic and vascular outcomes after transition to the MiniMed 780G system in adults ≥65 years with type 1 diabetes: a randomised, single-centre study.
Bartłomiej Matejko, Katarzyna Cyranka, Paulina Suduł et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the MiniMed 780G system's effectiveness in adults aged ≥65 years with type 1 diabetes. Among 34 participants, the advanced hybrid closed-loop therapy significantly improved time in range from 57.4% to 79.7% over 12 months (p<0.001), with no increase in hypoglycaemia. The study highlights the system's potential for glycaemic management in older adults.
Key findings
- Time in range increased from 57.4% at baseline to 79.7% at 12 months (p<0.001).
- Adjusted between-group difference for time in range was 15.7% (95% CI 8.6, 22.6).
- HbA1c decreased by 5 mmol/mol (95% CI -9.7, -0.4 mmol/mol).
- No serious adverse events or severe hypoglycaemia occurred during the study.
Why it matters
The findings suggest that the MiniMed 780G system can enhance glycaemic control in older adults with type 1 diabetes, a population often underrepresented in diabetes technology research. Improved management may lead to better overall health outcomes in this demographic.